Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SDCBP | O00560 | 8/20 | 0.56 |
| ▸ | SDC2 | P34741 | 8/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2181188 | 0.90 | ALOX15 (0.47) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL1500322 | 0.86 | SDCBP (0.59) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL2177628 | 0.85 | SDCBP (0.61) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL13574930 | 0.81 | SDCBP (0.52) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL2177896 | 0.80 | SDCBP (0.65) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL2181074 | 0.80 | MAPT (0.74) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL21929904 | 0.78 | SDCBP (0.51) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL21929871 | 0.78 | SDCBP (0.56) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL21612919 | 0.78 | SDCBP (0.76) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL2181199 | 0.78 | SDCBP (0.76) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748426-B2 | Inhibitors of diacylglycerol acyl transferase | Piramal Enterprises Limited (IN) | 2014-06-10 | — | — | US | disclosed |
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Enterprises Limited (IN) | 2012-11-15 | — | — | US | disclosed |
| EP-2519500-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Healthcare Ltd. (IN) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011080718-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | DGAT1, DGAT2, LCAT | SDCBP 2373/4885SDC2 3855/4885ALOX15 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.